Title:
（４Ｓ，４ＡＳ，５ＡＲ，１２ＡＳ）−４−ジメチルアミノ−３，１０，１２，１２Ａ−テトラヒドロキシ−７−［（メトキシ（メチル）アミノ）−メチル］−１，１１−ジオキソ−１，４，４Ａ，５，５Ａ，６，１１，１２Ａ−オクタヒドロ−ナフタセン−２−カルボン酸アミドの結晶塩及びそれを使用する方法
Document Type and Number:
Japanese Patent JP6574572
Kind Code:
B2
Abstract:
A crystalline mono hydrochloride salt of (4S,4aS,5aR,12aS)-4-dimethylamino- 3,10, 12, 12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]- 1, 11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide is disclosed having improved stability. In addition, a crystalline mono mesylate salt and crystalline mono sulfate salt of (4S,4aS,5aR,12aS)-4-dimethyl-amino-3,10,12,12a-tetrahydroxy-7- [(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene- 2-carboxylic acid amide are also disclosed having improved stability. A pharmaceutical composition containing the crystalline salts and methods of treating inflammatory skin disorders and bacterial infections comprising administering the crystalline salts are also disclosed.
Inventors:
Coulter, catherine
Johnston, Shawn, M.
Faedane, Seydi
Johnston, Shawn, M.
Faedane, Seydi
Application Number:
JP2014510546A
Publication Date:
September 11, 2019
Filing Date:
May 14, 2012
Export Citation:
Assignee:
Paratech Pharmaceuticals, Inc.
Warner Chilcot Company LRC
Warner Chilcot Company LRC
International Classes:
C07C239/20; A61K31/65; A61P17/00; A61P31/04; C07B57/00
Domestic Patent References:
| JP2010513527A | ||||
| JP2017132775A |
Foreign References:
| US20080312193 |
Other References:
芦澤一英編、医薬品の多形現象と晶析の科学、丸善プラネット株式会社、2002年9月20日発行、305-317頁
Attorney, Agent or Firm:
Yusuke Hiraki
Satoshi Fujita
Eiichi Arai
Natsuo Tanaka
Naoko Kikuta
Satoshi Fujita
Eiichi Arai
Natsuo Tanaka
Naoko Kikuta